New scanner could sharpen cancer radiation treatment

NCT ID NCT06681233

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new type of CT scanner called HyperSight, designed to produce clearer images during radiation therapy for cancer. About 50 adults with various cancers will receive their daily radiation using both the new and standard imaging. Researchers will compare image quality to see if HyperSight can help doctors better target tumors and reduce errors.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
HyperSight CBCT imaging device
What this could lead to
If successful, this could improve the accuracy and efficiency of daily radiation therapy for cancer patients by providing clearer images.
What could go wrong
This is an early feasibility study with only 50 participants, so results may not apply broadly. The new imaging may not show significant improvement over current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • James Outpatient Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Ohio State University, Brain and Spine Hospital

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Stefanie Spielman Comprehensive Breast Center

    RECRUITING

    Columbus, Ohio, 43212, United States

  • The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.